Research Progress on the Mechanism of Histone Deacetylases in Ferroptosis of Glioma.

IF 3.1 Q2 ONCOLOGY
Oncology Reviews Pub Date : 2024-08-12 eCollection Date: 2024-01-01 DOI:10.3389/or.2024.1432131
Meng Ma, Xifeng Fei, Dongyi Jiang, Hanchun Chen, Xiangtong Xie, Zhimin Wang, Qiang Huang
{"title":"Research Progress on the Mechanism of Histone Deacetylases in Ferroptosis of Glioma.","authors":"Meng Ma, Xifeng Fei, Dongyi Jiang, Hanchun Chen, Xiangtong Xie, Zhimin Wang, Qiang Huang","doi":"10.3389/or.2024.1432131","DOIUrl":null,"url":null,"abstract":"<p><p>Glioma is the most prevalent primary malignant tumor of the central nervous system. While traditional treatment modalities such as surgical resection, radiotherapy, and chemotherapy have made significant advancements in glioma treatment, the prognosis for glioma patients remains often unsatisfactory. Ferroptosis, a novel form of programmed cell death, plays a crucial role in glioma and is considered to be the most functionally rich programmed cell death process. Histone deacetylases have emerged as a key focus in regulating ferroptosis in glioma. By inhibiting the activity of histone deacetylases, histone deacetylase inhibitors elevate acetylation levels of both histones and non-histone proteins, thereby influencing various cellular processes. Numerous studies have demonstrated that histone deacetylases are implicated in the development of glioma and hold promise for its treatment. This article provides an overview of research progress on the mechanism by which histone deacetylases contribute to ferroptosis in glioma.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"18 ","pages":"1432131"},"PeriodicalIF":3.1000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348391/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/or.2024.1432131","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Glioma is the most prevalent primary malignant tumor of the central nervous system. While traditional treatment modalities such as surgical resection, radiotherapy, and chemotherapy have made significant advancements in glioma treatment, the prognosis for glioma patients remains often unsatisfactory. Ferroptosis, a novel form of programmed cell death, plays a crucial role in glioma and is considered to be the most functionally rich programmed cell death process. Histone deacetylases have emerged as a key focus in regulating ferroptosis in glioma. By inhibiting the activity of histone deacetylases, histone deacetylase inhibitors elevate acetylation levels of both histones and non-histone proteins, thereby influencing various cellular processes. Numerous studies have demonstrated that histone deacetylases are implicated in the development of glioma and hold promise for its treatment. This article provides an overview of research progress on the mechanism by which histone deacetylases contribute to ferroptosis in glioma.

组蛋白去乙酰化酶在胶质瘤铁变态反应中的作用机制研究进展。
胶质瘤是中枢神经系统最常见的原发性恶性肿瘤。虽然手术切除、放疗和化疗等传统治疗方式在胶质瘤治疗方面取得了重大进展,但胶质瘤患者的预后往往仍不令人满意。铁突变是细胞程序性死亡的一种新形式,在胶质瘤中起着至关重要的作用,被认为是功能最丰富的细胞程序性死亡过程。组蛋白去乙酰化酶已成为调控胶质瘤铁凋亡的关键焦点。通过抑制组蛋白去乙酰化酶的活性,组蛋白去乙酰化酶抑制剂可提高组蛋白和非组蛋白的乙酰化水平,从而影响各种细胞过程。大量研究表明,组蛋白去乙酰化酶与胶质瘤的发展有关,并有望用于治疗胶质瘤。本文概述了组蛋白去乙酰化酶促进胶质瘤铁变态反应机制的研究进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology Reviews
Oncology Reviews ONCOLOGY-
CiteScore
6.30
自引率
0.00%
发文量
9
审稿时长
9 weeks
期刊介绍: Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信